1 / 17

Intrepid Health Solutions Ematuzumab Launch

Intrepid Health Solutions Ematuzumab Launch. November 15, 2013 TEAM 1 David Waintraub Jason Bloom Manasa Parakala Michael Kwatkoski. Executive Summary. WHO?. HER2/ neu Breast Cancer Patients. WHAT?. Ematuzumab -Disruptive Monoclonal Antibody. WHERE?. Launch in the United States.

heaton
Download Presentation

Intrepid Health Solutions Ematuzumab Launch

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Intrepid Health SolutionsEmatuzumab Launch November 15, 2013 TEAM 1 David Waintraub Jason Bloom Manasa Parakala Michael Kwatkoski

  2. Executive Summary WHO? HER2/neu Breast Cancer Patients WHAT? Ematuzumab-Disruptive Monoclonal Antibody WHERE? Launch in the United States WHEN? FDA Approval by 2015 • Risk Sharing Pricing Model • High Overall Survival WHY? • High Complete Response Rate • No Cardiac Risk

  3. What is HER2/neu? • Biomarker: promotes cancer cell growth • Causes aggressive cancer • 38,400 diagnosed each year • Standard of Care: Genetech’s Herceptin • New Paradigm: Perjeta enhances Herceptin’s effectiveness

  4. Breast Cancer Continuum Before Surgery After Surgery Before/After Surgery Neo-Adjuvant Adjuvant Metastatic HER2/neu : 38,400 patients/year

  5. Perjeta Landscape Before Surgery After Surgery Before/After Surgery Neo-Adjuvant Adjuvant Metastatic P P P P P P E E E E E E

  6. Metastatic 1st Line: Ema vs. Perjeta Comparative Effectiveness Research

  7. Breast Cancer Continuum Before Surgery After Surgery Before/After Surgery Neo-Adjuvant Adjuvant Metastatic HER2/neu : 38,400 patients/year

  8. Neoadjuvant: Ema vs. Perjeta Comparative Effectiveness Research

  9. Breast Cancer Continuum Before Surgery After Surgery Before/After Surgery Neo-Adjuvant Adjuvant Metastatic HER2/neu : 38,400 patients/year

  10. Pricing Argument • Ematuzumab: $6500/month Perjeta: $5900/month • Comparative Effectiveness Research • Risk sharing model • Lower overall health care costs

  11. Comparative Effectiveness Research • Stronger Complete Response • Stronger Overall Survival • No Cardiac Risk

  12. Risk Sharing Model

  13. Lower Overall Healthcare Costs • Value Based Purchasing • Shifting story from price of drug to overall cost of care • High Complete Response • No Cardiac Risk • Accountable Care Organizations • Pay for total continuum of patient • Look at drug’s efficacy • Overall cost

  14. Better Drug, Better Plan • Have better results for less costs • Head to head studies • Risk sharing model • Uniform message to medical community • Payors, physicians, and patients

  15. Pre-Launch Plan • Timeline of Phase III Data • San Antonio Breast Cancer Symposium: December 2013 • Metastatic 1st Line Phase III Data • American Society of Clinical Oncology: June 2014 • Neo-Adjuvant Phase III Data

  16. Ema SWOT Analysis • STRENGTHS • Higher Complete Response • Higher Overall Survival • No Cardiac Risk • Innovative Pricing Model • WEAKNESSES • 2nd to Market • Genentech franchise • 1st time in oncology • Progression Free Survival • Longer drug administration • OPPORTUNITIES • Adjuvant • 2nd line metastatic • Potential to expand in oncology • THREATS • Phase III results weaker than projected • New product launches in the breast cancer space

  17. Questions?

More Related